Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells [PDF]
, 2012 DNA methylation might be the earliest somatic genome changes in prostate cancer that also play an important role in the process of tumor invasion, growth and metastasis.
D'Alessandro, Anna Maria +9 more
core +1 more source
Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. [PDF]
, 2014 BackgroundSince tumor suppressor gene function may be lost through hypermethylation, we assessed whether the demethylating agent decitabine could increase tumor suppressor gene expression clinically.
Aldaz, Marcelo +8 more
core +3 more sources
Inhibition of DNA methyltransferase leads to increased genomic 5-hydroxymethylcytosine levels in hematopoietic cells. [PDF]
, 2018 5-Hydroxymethylcytosine (5hmC) is produced from 5-methylcytosine (5mC) by Ten-eleven translocation (TET) dioxygenases. The epigenetic modification 5hmC has crucial roles in both cellular development and differentiation.
Apró, Anna +9 more
core +4 more sources
eJHaem, 2020 MLL‐rearranged acute lymphoblastic leukemia (ALL) represents a highly aggressive ALL subtype, characterized by aberrant DNA methylation patterns. DNA methyltransferase inhibitors, such as decitabine have previously been demonstrated to be effective in ...
Pauline Schneider +9 more
doaj +1 more source
p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia [PDF]
, 2011 Suppression of apoptosis by TP53 mutation contributes to resistance of acute myeloid leukemia (AML) to conventional cytotoxic treatment. Using differentiation to induce irreversible cell cycle exit in AML cells could be a p53-independent treatment ...
Anjali Advani +15 more
core +2 more sources
MedComm, 2023 Patients with relapsed/refractory classical Hodgkin lymphoma (cHL) achieve complete response (CR) after decitabine‐plus‐camrelizumab therapy, while long‐term outcome especially after treatment discontinuation remains unclear.
Chunmeng Wang +10 more
doaj +1 more source
MTSS1 is a critical epigenetically regulated tumor suppressor in CML [PDF]
, 2015 Chronic myeloid leukemia (CML) is driven by malignant stem cells that can persist despite therapy. We have identified Metastasis suppressor 1 (Mtss1/MIM) to be downregulated in hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr ...
Braunschweig, T. +18 more
core +1 more source
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia - a randomised SAL pilot study [PDF]
, 2012 INTRODUCTION: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in patients with low proliferating AML.
Berdel, Wolfgang E. +19 more
core +12 more sources
Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. [PDF]
PLoS ONE, 2014 Cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) reduces survival. In this study we hypothesized that methylation of key genes mediates cisplatin resistance.
Chi T Viet +5 more
doaj +1 more source
Application of Small Epigenetic Modulators in Pediatric Medulloblastoma [PDF]
, 2018 Medulloblastoma is one of the most frequent among pediatric brain tumors, and it has been classified in various subgroups. Some of them already benefit from quite good therapeutic options, whereas others urgently need novel therapeutic approaches ...
Annalisa Romanelli +8 more
core +2 more sources